Download PDF
Horm Metab Res 2001; 33(5): 295-299
DOI: 10.1055/s-2001-15286
Mini-Review

© Georg Thieme Verlag Stuttgart · New York

The Therapeutic Problem of Proliferative Diabetic Retinopathy: Targeting Somatostatin Receptors

M. I.  Davis, S. H.  Wilson, M. B.  Grant
  • Department of Pharmacology and Therapeutics, University of Florida College of Medicine, Gainesville, FL, USA
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

Clinical management of proliferative diabetic retinopathy has changed very little in the last 5 decades, relying primarily on laser ablation of the retinal vasculature. Several lines of clinical and experimental evidence suggest that somatostatin analogues may be efficacious in inhibiting neovascularization associated with proliferative retinopathy but the mechanism of action for these compounds is unclear. Inhibition of growth hormone secretion and the subsequent suppression of insulin-like growth factor 1 (IGF-1) production by somatostatin has been suggested as the mechanism of action, however, in vitro studies suggest that somatostatin analogues suppress endothelial cell growth through a direct, somatostatin receptor-mediated inhibition of pro-survival signaling pathways. The advent of a new generation of modified peptide and peptidomimetic somatostatin analogues has allowed investigators to more carefully define the receptor subtypes responsible for somatostatin-induced endothelial cell death and may eventually lead to the clinical development of somatostatin analogues that can reduce endothelial cell proliferation, independent of suppression of circulating hormone levels.

Key words:

Diabetic Retinopathy - Somatostatin - Octreotide - Apoptosis - Insulin-Like Growth Factor - Growth Hormone - Angiogenesis

References

  • 1 Albini A, Florio T, Giunciuglio D, Masiello L, Carlone S, Corsaro A, Thellung S, Cai T, Noonan D M, Schettini G. Somatostatin controls Kaposi’s sarcoma tumor growth through inhibition of angiogenesis.  FASEB J. 1999;  13 647-655
    PubMedGoogle Scholar
  • 2 Cattaneo M G, Amoroso D, Gussoni G, Sanguini A M, Vicentini L M. A somatostatin analogue inhibits MAP kinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines.  FEBS Lett. 1996;  397 (2 - 3) 164-168
    CrossrefPubMedGoogle Scholar
  • 3 Charland S, Boucher M J, Houde M, Rivard N. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells.  Endocrinology. 2001;  142 (1) 121-128
    CrossrefPubMedGoogle Scholar
  • 4 Douziech N, Calvo E, Coulombe Z, Muradia G, Bastien J, Aubin R A, Lajas A Morisset J. Inhibitory and stimulatory effects of somatostatin on two human pancreatic cancer cell lines: a primary role for tyrosine phosphatase SHP-1.  Endocrinology. 1999;  140 (2) 765-777
    CrossrefPubMedGoogle Scholar
  • 5 Lawnicka H, Stepien H, Wyczolkowska J, Kolago B, Kunert-Radek J, Komorowski J. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion form murine endothelial cell line (HECa10) culture.  Biochemical and Biophysical Research Communications. 2000;  268 567-571
    CrossrefPubMedGoogle Scholar
  • 6 Danesi R, Del Tacca M. The effects of the somatostatin analog octreotide on angiogenesis in vitro. .  Metabolism. 1996;  45 (8 Suppl. 1) 49-50
    PubMedGoogle Scholar
  • 7 Danesi R, Agen C, Benelli U, Paolo A D, Nardini D, Bocci G, Basolo F, Campagni A, Tacca M D. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201 - 995).  Clin Cancer Res. 1996;  3 (2) 265-272
    PubMedGoogle Scholar
  • 8 Lee H K, Suh K I, Koh C -S, Min H K, Lee J H, Chung H. Effect of SMS 201 - 995 in rapidly progressive diabetic retinopathy.  Diabetes Care. 1988;  11 (5) 441-443
    PubMedGoogle Scholar
  • 9 McCombe M, Lightman S, Eckland D J, Hamilton A M, Lightman S L. Effects of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: a pilot study.  Eye. 1991;  5 (Pt 5) 569-575
    PubMedGoogle Scholar
  • 10 Mallet B, Vialettes B, Haroche S, Escoffier P, Gastaut P, Taubert J P, Vague P. Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201 - 995.  Diabetes Metab. 1992;  18 (6) 438-444
    PubMedGoogle Scholar
  • 11 Grant M B, Mames R N, Fitzgerald C, Hazariwala K M, Cooper-De Hoff R, Caballero S, Estes K S. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study.  Diabetes Care. 2000;  23 (4) 504-509
    PubMedGoogle Scholar
  • 12 Smith L EH, Kopchick J J, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith R G, Schaeffer J M. Essential role of growth hormone in ischemia-induced retinal neovascularization.  Science. 1997;  276 (5319) 1706-1709
    CrossrefPubMedGoogle Scholar
  • 13 Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary hormone.  Science. 1973;  179 (68) 77-79
    CrossrefPubMedGoogle Scholar
  • 14 Patterson R H. Hypophysectomy: transfrontal technique and results in the management of metastatic cancer and diabetic retinopathy.  Clin Neurosurg. 1974;  21 60-67
    PubMedGoogle Scholar
  • 15 Arslan M. Ultrasonic selective hypophysectomy in Cushing’s disease, acromegaly and diabetic retinopathy.  Acta Otolaryngol. 1967;  63 (2) 252-263
    PubMedGoogle Scholar
  • 16 Kirkegaard C, Norgaard K, Snorgaard O, Bek T, Larsen M, Lund-Andersen H. Effect of one year continuous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus.  Acta Endocrinol. 1990;  122 (6) 766-772
    PubMedGoogle Scholar
  • 17 De los Frailes M T, Sanchez Franco F, Lorenzo M J, Tolon R, Cacicedo L. Influence of thyroid hormones on somatostatin processing in cultured cerebro-cortical cells.  Neuropeptides. 1990;  15 (1) 25-30
    CrossrefPubMedGoogle Scholar
  • 18 Lam K S, Wong R L. Thyroid hormones regulate the expression of somatostatin receptor subtypes in the rat pituitary.  Neuroendocrinology. 1999;  69 (6) 460-464
    CrossrefPubMedGoogle Scholar
  • 19 Merimee T j, Zapf J, Froesch E R. Insulin-like growth factors: Studies in diabetes with and without retinopathy.  N Engl J Med. 1983;  309 (9) 527-530
    PubMedGoogle Scholar
  • 20 Dills D G, Moss S E, Klein E K. Association of elevated IGF-1 levels with increased retinopathy in late-onset diabetes.  Diabetes. 1991;  40 1725-1730
    PubMedGoogle Scholar
  • 21 Grant M B, Tarnuzzer R W, Caballero S, Ozeck M J, Davis M I, Spoerri P E, Feokistov I, Biaggioni I, Shryock J C, Belardinelli L. Adenosine receptor activation induces vascular endothelial cell growth factor in human retinal endothelial cells.  Circ Res. 1999;  85 699-706
    PubMedGoogle Scholar
  • 22 Hyer S L, Sharp P S, Brooks R A, Burrin J M, Kohner E M. A two-year follow-up study of serum insulin-like growth factor-I in diabetics with retinopathy.  Metabolism. 1989;  38 (6) 586-589
    CrossrefPubMedGoogle Scholar
  • 23 Spranger J, Buhnen J, Jansen V, Krieg M, Meyer-Schwickerath R, Blum W F, Schatz H, Pfeiffer A FH. Systemic levels contribute significantly to increased intraocular IGF-I, IGF-II and IGF-BP3 in proliferative diabetic retinopathy.  Horm Metab Res. 2000;  32 (5) 196-200
    PubMedGoogle Scholar
  • 24 Ballintine E J, Foxman S, Gorden P, Roth J. Rarity of diabetic retinopathy in patients with acromegaly.  Arch Intern Med. 1981;  141 (12) 1625-1627
    CrossrefPubMedGoogle Scholar
  • 25 Amemiya T, Toibana M, Hashimoto M, Oseko F, Imura H. Diabetic retinopathy in acromegaly.  Opthalmologica. 1978;  176 (2) 74-80
    PubMedGoogle Scholar
  • 26 Smith L E, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff, Zhang B, Schaeffer J M, Senger D R. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1.  Nat Med. 1999;  5 (12) 1390-1395
    Google Scholar
  • 27 Rohrer S P, Birzin E T, Mosley R T, Berk S C, Hutchins S M, Shen D M, Xiong Y, Hayes E C, Parmar R M, Foor F, Mitra S W, Degrado D J, Shu M, Klopp J M, Cai S J, Blake A, Chan W WS, Pasternak A, Yang L, Patchett A A, Smith R G, Chapman K T, Schaeffer. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry.  Science. 1998;  282 737-740
    CrossrefPubMedGoogle Scholar
  • 28 Gillespie T J, Erenberg A, Kim S, Dong J, Taylor J E, Hau V, Davis T P. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution.  J Pharmocol Exp Therap. 1998;  285 (1) 95-104
    PubMedGoogle Scholar
  • 29 Tejada M, Gaal D, Schwab R E, Pap A Szuts T, Keri G. Influence of various administration routes on the antitumor efficacy of TT-232, a novel somatostatin analog.  Anticancer Res. 2000;  20 (2A) 1023-1027
    PubMedGoogle Scholar
  • 30 Teplan I. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity.  Acta Biol Hung. 2000;  51 (1) 1-29
    PubMedGoogle Scholar
  • 31 Bruns C, Raulf F, Hoyer D, Schloos J, Lubbert H, Weckbecker G. Binding properties of somatostatin receptor subtypes.  Metabolism. 1996;  45(Suppl 1) 17-20
    CrossrefPubMedGoogle Scholar
  • 32 Patel Y C, Srikant C B. Subtype selectivity of peptide analogs for all fine cloned human somatostatin receptors (hsstr1 - 5).  Endocrinology. 1994;  135 2814-2817
    CrossrefPubMedGoogle Scholar
  • 33 Reisine T, Bell G I. Molecular biology of somatostatin receptors.  Endocr Rev. 1995;  16 427-422
    CrossrefPubMedGoogle Scholar
  • 34 Shimon I, Taylor J E, Dong J Z, Bitonte R A, Kim S, Morgan B, Coy D H, Culler M D, Melmed S. Somatostatin receptor subtype specificity in human fetal pituitary culture.  J Clin Invest. 1997;  99 789-798
    CrossrefPubMedGoogle Scholar
  • 35 Cattaneo M G, Taylor J E, Culler M D, Nisoli E, Vicentini L M. Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells.  FEBS Letters. 2000;  481 271-276
    CrossrefPubMedGoogle Scholar
  • 36 Tran T -A, Mattern R -H, Afargan M, Amitay O, Ziv O, Morgan B A, Taylor J E, Hoyer D, Goodman M. Design, synthesis, and biological activities of potent and selective somatostatin analogues incorporating novel peptoid residues.  J Med Chem. 1998;  41 2679-2685
    CrossrefPubMedGoogle Scholar
  • 37 Parmar R M, Chan W W, Dashkevicz M, Hayes E C, Rohrer S P, Smith R G, Schaeffer JM Blake A D. Nonpeptidyl somatostatin agonists demonstrate that sst2 and sst5 inhibit stimulated growth hormone secretion from anterior pituitary cells.  Biochem Biophys Res Commin. 1999;  263 (2) 276-280
    PubMedGoogle Scholar
  • 38 Cattaneo M G, Scita G, Vicentini L M. Somatostatin inhibits PDGF-stimulated Ras activation in human neuroblastoma cells.  FEBS Lett. 1999;  459 (1) 64-68
    CrossrefPubMedGoogle Scholar
  • 39 Paques M, Massin P, Gaudric A. Growth factors and diabetic retinopathy.  Diabetes Metab. 1997;  23 (2) 125-130
    PubMedGoogle Scholar
  • 40 Grant M B, Caballero S, Millard W J. Inhibition of IGF-1 and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide, a potential treatment for ocular neovascularization.  Regul Pept. 1993;  48 267-278
    CrossrefPubMedGoogle Scholar
  • 41 Burghardt B, Barabas K, Marcsek Z, Flautner L, Gress T M, Varga G. Inhibitory effect of a long-acting somatotstatin analogue on EGF stimulated cell proliferation in Capan-2 cells.  J Physiol Paris. 2000;  94 (1) 57-62
    PubMedGoogle Scholar
  • 42 Wilson S H, Davis M I, Caballero S, Grant M B. Modulation of Retinal Endothelial Cell Behavior by IGF-1 and Somatostatin Analogues: Implications for Diabetic Retinopathy.  Growth Hormone and IGF Research. 2001;  in press
    PubMedGoogle Scholar
  • 43 Bruno J F, Xu Y, Song J, Berelowitz . Molecular cloning and functional expression of a novel brain specific somatostatin receptor.  Proc Nat Acad Sci USA. 1992;  89 11 151-11 155
    PubMedGoogle Scholar
  • 44 Law S, Manning D, Reisine T. Indentification of the subunits of GTP binding proteins coupled to somatostatin receptors.  J Biol Chem. 1991;  266 17 885-17 897
    PubMedGoogle Scholar
  • 45 Patel Y C, Greenwood M T, Warkszynska A, Panetta R, Srikant C B. Subtype selectivity of peptide analogues for all five cloned human somatostatin receptors (hsstr1 - 5).  Endocrinology. 1994;  135 (6) 2814-2817
    CrossrefPubMedGoogle Scholar
  • 46 Medina D L, Toro M J, Santisteban P. Somatostatin interferes with thyrotropin-induced G1-S transition mediated by cAMP-dependent protein kinase and phosphatidylinositol 3-kinase.  J Biol Chem. 2000;  275 (20) 15 549-15 556
    PubMedGoogle Scholar
  • 47 Pages P, Benali N, Saint-Laurent N, Esteve J P, Schally A V, Tkaczuk J, Vaysse N, Susini C, Buscail L. Sst2 somatostatin receptor mediates cell cycle arrest and induction of p27 (Kip1). Evidence for the role of SHP-1.  J Biol Chem. 1999;  274 (21) 15 186-15 193
    PubMedGoogle Scholar
  • 48 Thangaraju M, Sharma K, Leber B, Andrews D W, Shen S H, Srikant C B. Regulation of acidification and apoptosis by SHP-1 and Bcl-2.  J Biol Chem. 1999;  274 (41) 29 549-29 557
    PubMedGoogle Scholar
  • 49 Florio T, Thellung S, Arena S, Corsaro A, Bajetto A Schettini G, Stork P J. Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2.  J Physiol Paris. 2000;  94 (3 - 4) 239-250
    PubMedGoogle Scholar
  • 50 Reardon D B, Dent P, Wood S L, Knog T, Sturgill T W. Activation in vitro of somatostatin receptor subtype 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness.  Mol Endocrinol. 1997;  11 (8) 1062-1069
    CrossrefPubMedGoogle Scholar
  • 51 Charland S, Boucher M J, Houde M, Rivard N. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells.  Endocrinology. 2001;  142 (1) 121-128
    CrossrefPubMedGoogle Scholar
  • 52 Srikant C B. Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201 - 995 in AtT-20 mouse pituitary cells.  Biochem Biophys Res Commun. 1995;  209 (2) 400-406
    CrossrefPubMedGoogle Scholar
  • 53 Sharma K, Patel Y C, Srikant C B. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3.  Mol Endocrinol. 1996;  10 (12) 1688-1696
    CrossrefPubMedGoogle Scholar
  • 54 Sharma K, Srikant C B. Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells.  Int J Cancer. 1998;  76 (2) 259-66
    CrossrefPubMedGoogle Scholar

M. B. Grant

Department of Pharmacology and Therapeutics
University of Florida College of Medicine

P. O. Box 100267
Gainesville, Fl 32610
USA


Email: E-mail:grantma@pharmacology.ufl.edu

      >